Christoph B Olivier’s Team Explores Platelet Reactivity and Fibrin Clot-Strength in AF
Jan Hartmann, Chief Medical Officer at Haemonetics, reposted from Haemonetics on LinkedIn:
”Encouraging progress in personalized cardiovascular care.
A recent paper from Christoph B Olivier’s team at my alma mater, The University of Freiburg, explores “Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention”.
Their findings suggest that combined high platelet reactivity and increased platelet–fibrin clot strength after the PCI may elevate ischemic risk—though neither factor alone was predictive.
This aligns with data in broader post-PCI populations, with or without AFib:
- Young-Hoon Jeong, MD, PhD’s team (European Heart Journal, 2024) in South Korea showed that patients with combined platelet-fibrin clot strength and high platelet reactivity had the highest risk for MACE post-PCI (more than patients with either factor alone).
- A 2023 study from Fudan University in China reported similar results, where “a combination of high fibrinogen and HRPR may identify recurrent adverse ischemic events over 12 months.”
It’s encouraging to see continued momentum toward individualized post-intervention strategies, especially in tailoring OAC and antiplatelet therapy.
References:
Read the full article here.
Article: Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention
Authors: Diona Gjermeni, Hannah Vetter, Sofia Szabó, Viktoria Anfang, Carina Juelch, Stefan Leggewie, David Hesselbarth, Markus Jäckel, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B Olivier
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Jul 3, 2026, 19:15Edward Lee Carter: Anticoagulation Drift – The Patient Changes, the Plan Should Too
-
Jul 3, 2026, 19:15Marcelo Soares: Cytokine and Lymphocyte Profiles of Cancer Patients With COVID-19
-
Jul 3, 2026, 19:13Anwar Elshikh: Calciphylaxis and Skin Issues in Renal Failure Patients
-
Jul 3, 2026, 19:11Amr M. Fahmi: Genotype-Guided Warfarin Dosing in the Arab Population
-
Jul 3, 2026, 19:10Isabella Presch: A Step Toward Greater Regulatory Clarity in Genome-Editing Therapeutics
-
Jul 3, 2026, 18:24Alexandros Rampotas: Targeting Mutant CALR With Precision CAR-T Therapy
-
Jul 3, 2026, 18:08Ram Khandelwal: Why AI Is Transforming Patient Education and the Future of Healthcare
-
Jul 3, 2026, 17:55Miguel Bronchud: Why Congenital Neutropenia Is Often Missed
-
Jul 3, 2026, 17:35Patrick Rensen: Celebrating 25 Years in Endocrinology at Leiden University Medical Center